79. 家族性高コレステロール血症(ホモ接合体) Homozygous familial hypercholesterolemia Clinical trials / Disease details
臨床試験数 : 145 / 薬物数 : 114 - (DrugBank : 26) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 17
Showing 1 to 10 of 28 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2017-003170-13-AT (EUCTR) | 23/07/2019 | 11/02/2019 | Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hyperc ... | An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with homozygous familial hypercholesterolemia An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with hom ... | Homozygous familial hypercholesterolemia MedDRA version: 21.0;Level: LLT;Classification code 10020604;Term: Hypercholesterolemia;System Organ Class: 100000004861;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] Homozygous familial hypercholesterolemia MedDRA version: 21.0;Level: LLT;Classification code 1002060 ... | Product Name: Evinacumab (REGN1500) Product Code: REGN1500 INN or Proposed INN: Evinacumab Other descriptive name: EVINACUMAB Trade Name: Praluent INN or Proposed INN: ALIROCUMAB Other descriptive name: ALIROCUMAB Product Name: Evinacumab(REGN1500) Product Code: REGN1500 INN or Proposed INN: Evinacumab Other descrip ... | Regeneron Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 121 | Phase 3 | United States;Greece;Ukraine;Austria;United Kingdom;Italy;France;Czech Republic;Canada;Australia;South Africa;Germany;Netherlands;Japan United States;Greece;Ukraine;Austria;United Kingdom;Italy;France;Czech Republic;Canada;Australia;Sou ... | ||
2 | EUCTR2017-003170-13-IT (EUCTR) | 18/02/2019 | 22/01/2021 | Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hyperc ... | An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with homozygous familial hypercholesterolemia - na An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with hom ... | Homozygous familial hypercholesterolemia MedDRA version: 20.0;Level: LLT;Classification code 10057080;Term: Homozygous familial hypercholesterolemia;System Organ Class: 100000004850 MedDRA version: 20.0;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] Homozygous familial hypercholesterolemia MedDRA version: 20.0;Level: LLT;Classification code 1005708 ... | Trade Name: na Product Name: Evinacumab (REGN1500) Product Code: [REGN1500] INN or Proposed INN: Evinacumab Other descriptive name: Evinacumab Trade Name: Praluent Product Name: Praluent Product Code: [na] INN or Proposed INN: alirocumab Trade Name: na Product Name: Evinacumab(REGN1500) Product Code: [REGN1500] INN or Proposed INN: Evinacu ... | REGENERON PHARMACEUTICALS, INC. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 3 | United States;Czechia;Greece;Ukraine;Austria;United Kingdom;Italy;France;Czech Republic;Canada;Australia;South Africa;Norway;Germany;Netherlands;Japan United States;Czechia;Greece;Ukraine;Austria;United Kingdom;Italy;France;Czech Republic;Canada;Austr ... | ||
3 | EUCTR2017-003170-13-GR (EUCTR) | 01/02/2019 | 14/01/2019 | Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hyperc ... | An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with homozygous familial hypercholesterolemia An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with hom ... | Homozygous familial hypercholesterolemia MedDRA version: 21.0;Level: LLT;Classification code 10020604;Term: Hypercholesterolemia;System Organ Class: 100000004861;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] Homozygous familial hypercholesterolemia MedDRA version: 21.0;Level: LLT;Classification code 1002060 ... | Product Name: Evinacumab (REGN1500) Product Code: REGN1500 INN or Proposed INN: Evinacumab Other descriptive name: EVINACUMAB Trade Name: Praluent INN or Proposed INN: ALIROCUMAB Other descriptive name: ALIROCUMAB Product Name: Evinacumab(REGN1500) Product Code: REGN1500 INN or Proposed INN: Evinacumab Other descrip ... | Regeneron Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 121 | Phase 3 | United States;Czechia;Greece;Ukraine;Austria;United Kingdom;Italy;France;Czech Republic;Canada;Australia;South Africa;Germany;Netherlands;Japan United States;Czechia;Greece;Ukraine;Austria;United Kingdom;Italy;France;Czech Republic;Canada;Austr ... | ||
4 | EUCTR2017-003170-13-CZ (EUCTR) | 17/12/2018 | 11/10/2018 | Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hyperc ... | An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with homozygous familial hypercholesterolemia An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with hom ... | Homozygous familial hypercholesterolemia MedDRA version: 21.0;Level: LLT;Classification code 10020604;Term: Hypercholesterolemia;System Organ Class: 100000004861;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] Homozygous familial hypercholesterolemia MedDRA version: 21.0;Level: LLT;Classification code 1002060 ... | Product Name: Evinacumab (REGN1500) Product Code: REGN1500 INN or Proposed INN: Evinacumab Other descriptive name: EVINACUMAB Trade Name: Praluent INN or Proposed INN: ALIROCUMAB Other descriptive name: ALIROCUMAB Product Name: Evinacumab(REGN1500) Product Code: REGN1500 INN or Proposed INN: Evinacumab Other descrip ... | Regeneron Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 121 | Phase 3 | United States;Greece;Ukraine;Austria;United Kingdom;Italy;France;Czech Republic;Canada;Australia;South Africa;Germany;Netherlands;Japan United States;Greece;Ukraine;Austria;United Kingdom;Italy;France;Czech Republic;Canada;Australia;Sou ... | ||
5 | EUCTR2017-002297-39-SI (EUCTR) | 25/09/2018 | 20/06/2018 | An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Homozygous Familial Hypercholesterolemia An Efficacy and Safety Study of Alirocumabin Children and Adolescents with Homozygous Familial Hyper ... | An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Homozygous Familial Hypercholesterolemia An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumabin Children and Adolescents wit ... | Homozygous Familial Hypercholesterolemia MedDRA version: 20.0;Level: PT;Classification code 10020603;Term: Hypercholesterolaemia;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Homozygous Familial Hypercholesterolemia MedDRA version: 20.0;Level: PT;Classification code 10020603 ... | Product Name: Alirocumab Product Code: SAR236553 INN or Proposed INN: Alirocumab Other descriptive name: ALIROCUMAB Product Name: Alirocumab Product Code: SAR236553 INN or Proposed INN: Alirocumab Other descriptive name: ALIROCUMAB Product Name: Alirocumab Product Code: SAR236553 INN or Proposed INN: Alirocumab Other descriptive name ... | Sanofi-Aventis Recherche & Développement | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 3 | United States;Taiwan;Slovenia;Spain;Turkey;Austria;Russian Federation;Italy;France;Mexico;Canada;Argentina;Brazil;Denmark;Bulgaria;Norway;Netherlands United States;Taiwan;Slovenia;Spain;Turkey;Austria;Russian Federation;Italy;France;Mexico;Canada;Arg ... | ||
6 | EUCTR2017-002297-39-NO (EUCTR) | 19/09/2018 | 15/05/2018 | An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Homozygous Familial Hypercholesterolemia An Efficacy and Safety Study of Alirocumabin Children and Adolescents with Homozygous Familial Hyper ... | An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Homozygous Familial Hypercholesterolemia An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumabin Children and Adolescents wit ... | Homozygous Familial Hypercholesterolemia MedDRA version: 20.0;Level: PT;Classification code 10020603;Term: Hypercholesterolaemia;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Homozygous Familial Hypercholesterolemia MedDRA version: 20.0;Level: PT;Classification code 10020603 ... | Product Name: Alirocumab Product Code: SAR236553 INN or Proposed INN: Alirocumab Other descriptive name: ALIROCUMAB Product Name: Alirocumab Product Code: SAR236553 INN or Proposed INN: Alirocumab Other descriptive name: ALIROCUMAB Product Name: Alirocumab Product Code: SAR236553 INN or Proposed INN: Alirocumab Other descriptive name ... | Sanofi-Aventis Recherche & Développement | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 3 | Netherlands;United States;Taiwan;Slovenia;Spain;Turkey;Austria;Russian Federation;Italy;France;Mexico;Canada;Argentina;Brazil;Denmark;Bulgaria;Norway Netherlands;United States;Taiwan;Slovenia;Spain;Turkey;Austria;Russian Federation;Italy;France;Mexic ... | ||
7 | EUCTR2017-002297-39-BG (EUCTR) | 11/09/2018 | 31/07/2018 | An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Homozygous Familial Hypercholesterolemia An Efficacy and Safety Study of Alirocumabin Children and Adolescents with Homozygous Familial Hyper ... | An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Homozygous Familial Hypercholesterolemia An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumabin Children and Adolescents wit ... | Homozygous Familial Hypercholesterolemia MedDRA version: 20.0;Level: PT;Classification code 10020603;Term: Hypercholesterolaemia;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Homozygous Familial Hypercholesterolemia MedDRA version: 20.0;Level: PT;Classification code 10020603 ... | Product Name: Alirocumab Product Code: SAR236553 INN or Proposed INN: Alirocumab Other descriptive name: ALIROCUMAB Product Name: Alirocumab Product Code: SAR236553 INN or Proposed INN: Alirocumab Other descriptive name: ALIROCUMAB Product Name: Alirocumab Product Code: SAR236553 INN or Proposed INN: Alirocumab Other descriptive name ... | Sanofi-Aventis Recherche & Développement | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 3 | United States;Taiwan;Slovenia;Spain;Turkey;Austria;Russian Federation;Italy;France;Mexico;Canada;Argentina;Brazil;Denmark;Bulgaria;Netherlands;Norway United States;Taiwan;Slovenia;Spain;Turkey;Austria;Russian Federation;Italy;France;Mexico;Canada;Arg ... | ||
8 | EUCTR2017-002297-39-AT (EUCTR) | 04/09/2018 | 07/06/2018 | An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Homozygous Familial Hypercholesterolemia An Efficacy and Safety Study of Alirocumabin Children and Adolescents with Homozygous Familial Hyper ... | An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Homozygous Familial Hypercholesterolemia An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumabin Children and Adolescents wit ... | Homozygous Familial Hypercholesterolemia MedDRA version: 20.0;Level: PT;Classification code 10020603;Term: Hypercholesterolaemia;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Homozygous Familial Hypercholesterolemia MedDRA version: 20.0;Level: PT;Classification code 10020603 ... | Product Name: Alirocumab Product Code: SAR236553 INN or Proposed INN: Alirocumab Other descriptive name: ALIROCUMAB Product Name: Alirocumab Product Code: SAR236553 INN or Proposed INN: Alirocumab Other descriptive name: ALIROCUMAB Product Name: Alirocumab Product Code: SAR236553 INN or Proposed INN: Alirocumab Other descriptive name ... | Sanofi-Aventis Recherche & Développement | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 3 | Austria;United States;Taiwan;Slovenia;Spain;Turkey;Russian Federation;Italy;France;Mexico;Canada;Argentina;Brazil;Denmark;Bulgaria;Netherlands;Norway Austria;United States;Taiwan;Slovenia;Spain;Turkey;Russian Federation;Italy;France;Mexico;Canada;Arg ... | ||
9 | EUCTR2017-002297-39-DK (EUCTR) | 03/09/2018 | 04/06/2018 | An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Homozygous Familial Hypercholesterolemia An Efficacy and Safety Study of Alirocumabin Children and Adolescents with Homozygous Familial Hyper ... | An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Homozygous Familial Hypercholesterolemia An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumabin Children and Adolescents wit ... | Homozygous Familial Hypercholesterolemia MedDRA version: 20.0;Level: PT;Classification code 10020603;Term: Hypercholesterolaemia;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Homozygous Familial Hypercholesterolemia MedDRA version: 20.0;Level: PT;Classification code 10020603 ... | Trade Name: Praluent Product Name: Alirocumab Product Code: SAR236553 INN or Proposed INN: Alirocumab Other descriptive name: ALIROCUMAB Trade Name: Praluent Product Name: Alirocumab Product Code: SAR236553 INN or Proposed INN: Alirocumab Other descriptive name: ALIROCUMAB Trade Name: Praluent Product Name: Alirocumab Product Code: SAR236553 INN or Proposed INN: Alirocumab Ot ... | Sanofi-Aventis Recherche & Développement | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 3 | United States;Taiwan;Slovenia;Spain;Turkey;Austria;Russian Federation;Italy;France;Mexico;Canada;Argentina;Brazil;Denmark;Bulgaria;Netherlands;Norway United States;Taiwan;Slovenia;Spain;Turkey;Austria;Russian Federation;Italy;France;Mexico;Canada;Arg ... | ||
10 | NCT03510715 (ClinicalTrials.gov) | August 31, 2018 | 18/4/2018 | An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia An Efficacy and Safety Study of Alirocumabin Children and Adolescents With Homozygous Familial Hyper ... | An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumabin Children and Adolescents Wit ... | Hypercholesterolemia | Drug: Alirocumab SAR236553 (REGN727);Drug: Rosuvastatin;Drug: Ezetimibe;Drug: Cholestyramine;Drug: Nicotinic acid;Drug: Fenofibrate;Drug: Omega-3 fatty acids;Drug: Atorvastatin;Drug: Simvastatin;Drug: Fluvastatin;Drug: Pravastatin;Drug: Lovastatin Drug: AlirocumabSAR236553 (REGN727);Drug: Rosuvastatin;Drug: Ezetimibe;Drug: Cholestyramine;Drug: Ni ... | Sanofi | Regeneron Pharmaceuticals | Completed | 8 Years | 17 Years | All | 18 | Phase 3 | Brazil;Canada;Denmark;Mexico;Netherlands;Russian Federation;Slovenia;Spain;Taiwan;Turkey;Austria;France;Italy;Norway;United States Brazil;Canada;Denmark;Mexico;Netherlands;Russian Federation;Slovenia;Spain;Taiwan;Turkey;Austria;Fra ... |